December 4, 2019

Grifols introduces its first plasma protein-based biosurgery product

  • VISTASEAL™, a fibrin sealant developed by Grifols for biosurgical bleeding-control, is marketed and distributed by Ethicon and is the result of the two companies’ strategic collaboration
  • VISTASEAL™ contains a combination of two plasma proteins (fibrinogen and thrombin) administered with Ethicon’s innovative device

Barcelona, Spain, December 4, 2019 – Grifols, (MCE: GRF; MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with more than 100 years dedicated to enhancing people’s health and well-being and a leader in plasma medicines, transfusion diagnosis and pharmaceutical specialties for hospital use, today introduced VISTASEAL™, its first plasma-protein-based biosurgery solution.

VISTASEAL™ is a fibrin sealant for surgical bleeding-control that combines two plasma proteins (fibrinogen and thrombin) administered with Ethicon’s airless spray device technology.

The collaboration combines Grifols’ ability to produce critical plasma-based therapies with Ethicon’s expertise in developing device technology. Ethicon, a Johnson & Johnson Medical Devices Company, is commercializing and distributing VISTASEAL™ in the U.S.

Eduardo Herrero, President Grifols Bioscience Industrial Group, said: “VISTASEAL™ is the result of our continuous efforts to innovate and a commitment to in-house R&D projects. We will continue to investigate and explore different areas of medicine with unmet needs in which plasma proteins can add value. In this sense, biosurgery is a field full of potential for us in which we count on a sound, strategic ally in Ethicon.”

The VISTASEAL™ biological components are produced in the industrial complex of Parets del Vallés (Barcelona, Spain), which has a production capacity of over 300,000 units, as well as capacity to expand to 3 million equivalent liters of plasma.